ACE and coronary artery disorder: However, with regards to mean age, proportion of male participants and use of preventive pharmacotherapy the present sample is comparable to CAD patients in the EU-wide DA VINCI registry on lipid-lowering therapy (mean age 67 years, 76% male, statins 94%) as well as to German CAD patients of the EUROASPIRE IV and V registries on cardiovascular risk factor control (mean age 69 years; 81–82% male, statins 87–97%, ACE-inhibitors or angiotensin receptor-blockers 86–93%, betablockers 79–87%) [24, 46].